Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Trial Profile

Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs AKB 9778 (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms TIME-2b
  • Sponsors Aerpio Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2017 According to an Aerpio Pharmaceuticals media release, the company has initiated patient dosing in this trial. Victor H. Gonzalez has enrolled the first patient in this trial.
    • 22 Jun 2017 Status changed from planning to recruiting.
    • 18 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top